ACRS
Aclaris Therapeutics Inc
NASDAQ: ACRS · HEALTHCARE · BIOTECHNOLOGY
$4.47
+5.92% today
Updated 2026-04-29
Market cap
$624.30M
P/E ratio
—
P/S ratio
79.77x
EPS (TTM)
$-0.53
Dividend yield
—
52W range
$1 – $5
Volume
2.0M
Aclaris Therapeutics Inc (ACRS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $14.21M | $17.38M | $94.08M | $176.09M | $243.51M | $275.57M | $98.30M | $70.78M | $251.21M | $254.60M | $197.41M | $220.33M |
| Cash & equivalents | $9.59M | $10.76M | $9.85M | $30.17M | $208.85M | $57.02M | $35.94M | $22.06M | $27.35M | $45.28M | $39.88M | $24.57M |
| Current assets | $13.39M | $16.33M | $92.04M | $174.13M | $208.85M | $179.50M | $83.80M | $57.49M | $205.03M | $231.55M | $128.86M | $125.95M |
| Total liabilities | $23.37M | $38.13M | $1.55M | $6.59M | $18.25M | $60.44M | $28.39M | $33.13M | $53.87M | $56.98M | $40.23M | $64.77M |
| Current liabilities | $367000.00 | $1.45M | $1.55M | $6.22M | $12.76M | $27.34M | $22.43M | $14.87M | $22.93M | $21.94M | $30.95M | $31.60M |
| Long-term debt | — | — | $0.00 | $0.00 | $261000.00 | $29.91M | — | $10.65M | — | — | — | — |
| Shareholder equity | $-9.16M | $-20.75M | $92.52M | $169.49M | $225.26M | $215.12M | $69.91M | $37.65M | $197.34M | $197.62M | $157.18M | $155.55M |
| Retained earnings | $-9.17M | $-20.75M | $-42.83M | $-90.91M | $-159.44M | $-292.17M | $-453.53M | $-504.54M | $-595.41M | $-682.32M | $-770.80M | $-902.86M |
| Accounts receivable | — | — | $22000.00 | — | $481000.00 | $563000.00 | $704000.00 | $772000.00 | $623000.00 | $484000.00 | $298000.00 | $318000.00 |
| Inventory | — | — | $0.00 | $0.00 | $-6.36M | $791000.00 | $4.97M | — | $-34.24M | $-12.24M | — | — |
| Goodwill | — | — | $0.00 | $0.00 | $18.50M | $18.50M | $0.00 | — | — | — | — | — |